RxDoctor Payments Data

Bshara Barakat, MD

Internal Medicine · Jacksonville, FLNPI 1518921360

Payments from drug & device makers

$965in general payments, 2019–2025

Across 54 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$161
  • Amgen$124
  • Novo Nordisk$116
  • UCB, Inc.$100
  • E.r. Squibb & Sons, L.L.C.$81
  • Mallinckrodt Enterprises LLC$77
  • plus $306 from 10 others

What the payments were for

  • Food & beverage$93297%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$965 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$296,274
Medicare patients
205
Services billed
2,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$77,489
RybelsusSemaglutide54$61,758
EliquisApixaban44$39,349
FarxigaDapagliflozin Propanediol31$28,583
MounjaroTirzepatide21$28,292
Tresiba Flextouch U-200Insulin Degludec13$22,399
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,910
Breo ElliptaFluticasone/Vilanterol11$5,823
Omeprazole152$2,550
Albuterol Sulfate HfaAlbuterol Sulfate92$2,519
Atorvastatin Calcium289$2,492
Levothyroxine Sodium219$2,268
SynthroidLevothyroxine Sodium39$2,232
Clonidine31$2,176
Losartan Potassium193$1,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$139,247110 claims
AstraZenecaFarxiga$19$28,58331 claims
GSKAnoro Ellipta, Breo Ellipta$53$14,73330 claims
AbbVieSynthroid$50$2,23239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →